RxDoctor Payments Data

John Lazarus, MD

Cardiovascular Disease · Lancaster, OHNPI 1336434729

Payments from drug & device makers

$16,635in general payments, 2019–2025

Across 230 payments — averaging $72.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$11K
  • Boston Scientific$3K
  • Novartis$576
  • AstraZeneca$398
  • Johnson & Johnson$319
  • Pfizer$316
  • plus $991 from 16 others

What the payments were for

  • Grants$1231%
  • Travel & lodging$10,85765%
  • Food & beverage$5,49633%
  • Education$1591%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,635 in reported general payments places this provider in the 80th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$165,007
Medicare patients
920
Services billed
1,947

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban260$194,975
XareltoRivaroxaban41$40,762
Repatha SureclickEvolocumab36$39,077
EntrestoSacubitril/Valsartan43$34,377
Praluent PenAlirocumab15$12,914
MultaqDronedarone Hcl12$12,358
FarxigaDapagliflozin Propanediol15$11,541
Soliqua 100-33Insulin Glargine/Lixisenatide12$10,898
Prasugrel Hcl36$7,504
Atorvastatin Calcium449$4,986
Ranolazine ErRanolazine45$4,209
ClopidogrelClopidogrel Bisulfate388$3,829
Metoprolol Succinate302$3,559
Potassium Chloride117$2,238
Carvedilol312$2,027

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$316$194,975260 claims
Johnson & JohnsonXarelto$319$40,76241 claims
NovartisEntresto$576$34,37743 claims
Sanofi-aventis U.S. LLCMultaq, Soliqua 100-33$17$23,25724 claims
AstraZenecaFarxiga$398$11,54115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Lancaster

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →